|
KMID : 1148920200540020114
|
|
Nuclear Medicine and Molecular Imaging
2020 Volume.54 No. 2 p.114 ~ p.119
|
|
|
First In-Human Medical Imaging with a PASylated 89Zr-Labeled Anti-HER2 Fab-Fragment in a Patient with Metastatic Breast Cancer
|
|
Richter Antonia
Knorr Karina
Schlapschy Martin
Robu Stephanie
Morath Volker
Mendler Claudia
Yen Hsi-Yu
Steiger Katja
Kiechle Marion
Weber Wolfgang
Skerra Arne
Schwaiger Markus
|
|
|
Abstract
|
|
|
Purpose: PASylation® offers the ability to systematically tune and optimize the pharmacokinetics of protein tracers for molecular imaging. Here we report the first clinical translation of a PASylated Fab fragment (89Zr?Df-HER2-Fab-PAS200) for the molecular imaging of tumor-related HER2 expression.
Methods: A patient with HER2-positive metastatic breast cancer received 37 MBq of 89Zr?Df-HER2-Fab-PAS200 at a total mass dose of 70 μg. PET/CT was carried out 6, 24, and 45 h after injection, followed by image analysis of biodistribution, normal organ uptake, and lesion targeting.
Results: Images show a biodistribution typical for protein tracers, characterized by a prominent blood pool 6 h p.i., which decreased over time. Lesions were detectable as early as 24 h p.i. 89Zr?Df-HER2-Fab-PAS200 was tolerated well.
Conclusion: This study demonstrates that a PASylated Fab tracer shows appropriate blood clearance to allow sensitive visualization of small tumor lesions in a clinical setting.
|
|
|
KEYWORD
|
|
|
Breast cancer (BCa), Fab fragment, Human epidermal growth factor receptor 2 (HER2), Imaging, PASylation, 89Zr
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|